Rese Cel Autoimmune Follow Up Reaches One Year

Cabaletta disclosed updated single-arm rese-cel outcomes across autoimmune cohorts. Six of six dermatomyositis patients maintained immunomodulator-free moderate-to-major TIS responses at one year. The signal is clinically meaningful but small-cohort selection, optional biopsies and lack…





